VAXX - Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024 | Benzinga
CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson's disease and preclinical data from its anti-tau program in Alzheimer's disease at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD 2024), taking place March 5-9, 2024 virtually and in Lisbon, Portugal.
Presentation details are as follows:
Oral Presentation
Title: Evidence of Target Engagement in a Phase 1 Clinical Trial of UB-312 in Parkinson's Disease
Presenter: Jean-Cosme Dodart, Ph.D., SVP of Research at Vaxxinity
Location: Auditorium VIII
Date & Time: March 6, 2024 at 6:00 PM WET
Poster Presentation
Title: A Randomized, Double Blind, Placebo-Controlled Study with UB-312, an Anti-Alpha-Synuclein Peptide Vaccine in Parkinson's Disease Patients
Poster Number: P1049 / #720
Authors: Pepijn Eijsvogel, Hui Jing Yu, Philip Kremer, Lauren Fedor, Igor Radanovic, Dario Mirski, Maurits Vissers, Marieke De Kam, Jean-Cosme Dodart, Geert Jan Groeneveld
Poster Presentation
Title: Efficacy of a New Vaccine Targeting Tau in Mouse Models
Poster Number: P0770 / #1617
Authors: Christopher Brown, Louise Kelly, Jeanne Brooks, Matthew Longo, Justin Boyd, Roxana Carare, Jean-Cosme Dodart
About Vaxxinity
Vaxxinity, Inc. is a purpose-driven biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of medicines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome ...